You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023166010
Dec 20235506
Jan 20243404
Feb 20243801
Mar 20244805
Apr 20248407
May 20244806
Jun 20241601
Jul 20241800
Aug 20242802
Sep 20241800
Oct 20244403
Nov 20244606
Dec 20241404
Jan 20254408
Feb 2025403
Mar 2025003
Apr 2025105
May 2025004
Jun 2025003
Total706081